Tivic Health Systems Inc
Research Tivic Health Systems Inc (TIVC) on Bullrun: market cap USD 2.53M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTIVC
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 2.53M
- Financial periodFY2025
- RevenueUSD 0
- Net income-USD 8.88M
- Free cash flow-USD 7.58M
Valuation Snapshot
latest market cap is USD 2.53M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 8.88M | -USD 7.58M | n/a | n/a | USD 12.65M | USD 6.45M | USD 16.80M |
| FY2024 | USD 0 | -USD 5.66M | -USD 5.73M | n/a | -19.68 | USD 2.00M | USD 0 | USD 2.54M |
| FY2023 | USD 1.18M | -USD 8.24M | -USD 8.63M | 24.4% | -176.8 | USD 3.40M | USD 369.00K | USD 3.58M |
| FY2022 | USD 1.84M | -USD 10.10M | -USD 8.93M | 16.3% | -1768 | USD 3.52M | USD 530.00K | USD 3.63M |
| FY2021 | USD 1.26M | -USD 8.49M | -USD 5.61M | -3.0% | -4131 | USD 12.98M | USD 708.00K | USD 13.27M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-05-15 | USD 2.53M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.66M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.28M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.64M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 6.20M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 37.60M | n/a | n/a | n/a |
About Tivic Health Systems Inc
Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tivic Health Systems Inc's market cap?
Tivic Health Systems Inc's market capitalization is USD 2.53M.
What does Tivic Health Systems Inc do?
Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026.